Singapore-based PrestigePharma presents fresh equivalency data supporting its case for regulatory approval of HD201.
Positive pharmacokinetic (PK) equivalency data were presented for PrestigePharma’s trastuzumab biosimilar candidate (HD201, Tuznue), at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
PrestigePharma is a Singapore-based biopharmaceutical company that has an application for HD201 under review with the European Medicines Agency. The company previously reported positive biosimilarity findings for HD201 at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology.
In the ESMO data, PrestigePharma reported PK equivalence between HD201 and 2 versions of the reference product sold in the United States (US-Herceptin) and Europe (EU Herceptin), based on findings from a randomized, phase 1 trial (TROIKA-I, NCT03776240). Investigators said 105 healthy male subjects randomized to 3 arms received the biosimilar candidate and reference versions at an intravenous dose of 6 mg/kg for 90 minutes.
Study End Points
The HD201 and Herceptin trastuzumab versions were compared based on primary end points including peak concentration and total drug exposure. PK equivalence for HD201 was considered met if the confidence intervals were within conventional equivalence margins of 80% and 125%. Secondary end points included other PK parameters, safety, tolerability, and immunogenicity.
Investigators said HD201 demonstrated PK equivalence for all criteria. They said the incidence of adverse events was lower in the HD201 cohort (20%) compared with the EU Herceptin (34.3%) and US-Herceptin (31.4%) groups. The most common adverse events were infusion-related reactions and administration site reactions.
At ASCO, findings were presented from TROIKA-I and TROIKA, which involved patients with HER2-positive early stage breast cancer. These earlier results indicated that the biosimilar was safe and well tolerated with PK comparable to Herceptin. In TROIKA, patients received HD201 or EU-Herceptin with chemotherapy in the neoadjuvant setting followed by trastuzumab monotherapy in the adjuvant phase.
The total pathological complete response rate was 46.6% for patients in the HD201 arm versus 46.2% in the Herceptin arm. The overall response rate was 90.8% vs 89.4%, respectively. TROIKA had 574 patents evaluable for response for the ASCO report, and the study remains ongoing (NCT03013504).
HD201 is the lead biosimilar candidate under development at PrestigePharma. The company also has bevacizumab and adalimumab biosimilars in development.
Reference
Demarchi M, Coliat P, Chung Shii Hii J, et al. A double-blind, randomized, parallel group study to demonstrate the equivalent pharmacokinetic properties of a single intravenous dose HD201, a trastuzumab biosimilar candidate, versus EU trastuzumab and US trastuzumab. Poster presented at ESMO Virtual Congress 2020; September 17, 2020. Abstract 590P.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.